A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) (PODO)
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) (PODO)
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 44 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: A PHASE 2, 12 WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Actual Study Start Date: October 15, 2018
Estimated Primary Completion Date: February 5, 2024
Estimated Study Completion Date: February 5, 2024
Arm:
- Experimental: PF-06730512 Cohort 1
- Experimental: PF-06730512 Cohort 2
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 44 |
| Actual Study start date | 15 October 2018 |
| Estimated Study Completion Date | 05 February 2024 |